Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia,

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.7, indicating a -1

Ten stocks worth more than $2 billion each have more than a third of their float sold short. At the

Ten stocks have over 34% of their float short, with ONDS and BROS on the list led by VG.

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and pro

Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursi

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data lic

Recursion Pharmaceuticals (NASDAQ: RXRX) outlined its strategy, clinical pipeline and partnership pr

Recursion Pharmaceuticals NASDAQ: RXRX outlined its strategy, clinical pipeline and partnership prog

Recursion Pharmaceuticals (NASDAQ:RXRX) reported second-quarter financial results on Wednesday. The

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% mo

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conf

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71%

Don't catch a falling knife.

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?

AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season i

Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with

Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on posi

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing

Recursion Pharmaceuticals (NASDAQ: RXRX) is using artificial intelligence to generate and analyze bi

Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biol

Cramer likes Vistra and Constellation, but not NextEra. Recursion and Fastly reported weak earnings,

California State Teachers Retirement System lifted its holdings in Recursion Pharmaceuticals, Inc. (

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Trans

Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch g

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth chall

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.25) per share which missed

Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A de

Morgan Stanley analyst Vikram Purohit maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Eq

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and mainta

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.22) per share which beat th

JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overwe

Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded

B of A Securities analyst Michael Ryskin maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and mainta

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are surging Wednesday following a robust earnings

ARK's 2025 winners included Robinhood, AMD and Palantir, while its losers were The Trade Desk, R

Here's a look at the earnings calendar for the week ahead, including reports from Nvidia, Joby,

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are under pressure Wednesday after new regulatory

Wall Street ends 2026 positively with tech stocks dominating, but concerns over valuations drive int